KJ Muldoon received a groundbreaking new treatment earlier this year. The baby saved from a rare disease by a first-ever personalized gene fix has reached a big milestone, taking his first steps ahead ...

DelveInsight's,“ Myelodysplastic Syndrome Pipeline Insights 2025” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It ...

Introduction: Acute promyelocytic leukemia (APL) features leukemic cell differentiation arrest at the promyelocytic stage, mainly due to the t (15;17), (q24; q21) translocation that forms the PML-RARA ...

In recent years, significant attention has been paid to the identification of individual genomic characteristics, particularly with the growing focus on personalized therapy across various research ...

Alex Sundby is a senior editor at CBSNews.com. In addition to editing content, Alex also covers breaking news, writing about crime and severe weather as well as everything from multistate lottery ...

The search for gene therapies to treat rheumatoid arthritis (RA) has moved in fits and starts over the past two decades, with trials starting and stopping, and their focus shifting to osteoarthritis ...

The phase 3 trial for high-risk MDS with RARA overexpression did not achieve its primary endpoint of CR rate. Tamibarotene-Vidaza treatment showed a 23.8% CR rate, not significantly different from the ...

Syros Pharmaceuticals Inc SYRS revealed on Tuesday that the SELECT-MDS-1 Phase 3 trial of tamibarotene did not meet its primary endpoint of complete response rate. The trial assessed tamibarotene in ...

Shares of Syros Pharmaceuticals Inc. (NASDAQ:SYRS) tumbled 86%, or $2.35, to trade at 86 cents after the firm said the phase III study testing tamibarotene in myelodysplastic syndrome (MDS) patients ...

NEW YORK – Syros Pharmaceuticals said on Tuesday that its retinoic acid receptor-alpha agonist tamibarotene, which it was testing in combination with azacitidine in patients newly diagnosed with ...